(Q35826471)

10 August 2017

1 reference

title

Epratuzumab in non-Hodgkin's lymphomas (English)

1 reference

10 August 2017

Richard R Furman

1

1 reference

10 August 2017

Morton Coleman

series ordinal

2

1 reference

10 August 2017

John P Leonard

series ordinal

3

1 reference

10 August 2017

publication date

1 August 2004

1 reference

Current Treatment Options in Oncology

10 August 2017

published in

1 reference

10 August 2017

volume

5

1 reference

10 August 2017

issue

4

1 reference

10 August 2017

page(s)

283-288

1 reference

Specifically targeting the CD22 receptor of human B-cell lymphomas with RNA damaging agents: a new generation of therapeutics

10 August 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11864-004-0019-1

Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results.

21 January 2018

1 reference

12 December 2020

Waldenström macroglobulinemia. Development of diagnostic criteria and identification of prognostic factors

1 reference

12 December 2020

Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia

1 reference

12 December 2020

Constitutive endocytosis and degradation of CD22 by human B cells

1 reference

12 December 2020

CD22, a B lymphocyte-specific adhesion molecule that regulates antigen receptor signaling.

1 reference

12 December 2020

CD22 negatively and positively regulates signal transduction through the B lymphocyte antigen receptor

1 reference

12 December 2020

cDNA cloning of the B cell membrane protein CD22: a mediator of B-B cell interactions

1 reference

12 December 2020

CD22 regulates thymus-independent responses and the lifespan of B cells.

1 reference

12 December 2020

Construction and characterization of a humanized, internalizing, B-cell (CD22)-specific, leukemia/lymphoma antibody, LL2.

1 reference

12 December 2020

Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma

1 reference

12 December 2020

Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties

1 reference

12 December 2020

Identification of CD22 ligands on bone marrow sinusoidal endothelium implicated in CD22-dependent homing of recirculating B cells

1 reference

12 December 2020

B cell inhibitory receptors and autoimmunity.

1 reference

12 December 2020

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

1 reference

12 December 2020

Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma

1 reference

12 December 2020

Final results of a phase I radioimmunotherapy trial using (186)Re-epratuzumab for the treatment of patients with non-Hodgkin's lymphoma

1 reference

12 December 2020

10.1007/S11864-004-0019-1

Identifiers

DOI

1 reference

10 August 2017

1 reference